Cargando…

Skin collagen advanced glycation endproducts (AGEs) and the long-term progression of sub-clinical cardiovascular disease in type 1 diabetes

BACKGROUND: We recently reported strong associations between eight skin collagen AGEs and two solubility markers from skin biopsies obtained at DCCT study closeout and the long-term progression of microvascular disease in EDIC, despite adjustment for mean glycemia. Herein we investigated the hypothe...

Descripción completa

Detalles Bibliográficos
Autores principales: Monnier, Vincent M, Sun, Wanjie, Gao, Xiaoyu, Sell, David R, Cleary, Patricia A, Lachin, John M, Genuth, Saul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4560872/
https://www.ncbi.nlm.nih.gov/pubmed/26341632
http://dx.doi.org/10.1186/s12933-015-0266-4
_version_ 1782388972037603328
author Monnier, Vincent M
Sun, Wanjie
Gao, Xiaoyu
Sell, David R
Cleary, Patricia A
Lachin, John M
Genuth, Saul
author_facet Monnier, Vincent M
Sun, Wanjie
Gao, Xiaoyu
Sell, David R
Cleary, Patricia A
Lachin, John M
Genuth, Saul
author_sort Monnier, Vincent M
collection PubMed
description BACKGROUND: We recently reported strong associations between eight skin collagen AGEs and two solubility markers from skin biopsies obtained at DCCT study closeout and the long-term progression of microvascular disease in EDIC, despite adjustment for mean glycemia. Herein we investigated the hypothesis that some of these AGEs (fluorescence to be reported elsewhere) correlate with long-term subclinical cardiovascular disease (CVD) measurements, i.e. coronary artery calcium score (CAC) at EDIC year 7–9 (n = 187), change of carotid intima-media thickness (IMT) from EDIC year 1 to year 6 and 12 (n = 127), and cardiac MRI outcomes at EDIC year 15–16 (n = 142). METHODS: Skin collagen AGE measurements obtained from stored specimens were related to clinical data from the DCCT/EDIC using Spearman correlations and multivariable logistic regression analyses. RESULTS: Spearman correlations showed furosine (early glycation) was associated with future mean CAC (p < 0.05) and CAC >0 (p = 0.39), but not with CAC score <100 vs. >100. Glucosepane and pentosidine crosslinks, methylglyoxal hydroimidazolones (MG-H1) and pepsin solubility (inversely) correlated with IMT change from year 1 to 6(all P < 0.05). Left ventricular (LV) mass (cMRI) correlated with MG-H1, and inversely with pepsin solubility (both p < 0.05), while the ratio LV mass/end diastolic volume correlated with furosine and MG-H1 (both p < 0.05), and highly with CML (p < 0.01). In multivariate analysis only furosine (p = 0.01) was associated with CAC. In contrast IMT was inversely associated with lower collagen pepsin solubility and positively with glucosepane, CONCLUSIONS: In type 1 diabetes, multiple AGEs are associated with IMT progression in spite of adjustment for A1c implying a likely participatory role of glycation and AGE mediated crosslinking on matrix accumulation in coronary arteries. This may also apply to functional cardiac MRI outcomes, especially left ventricular mass. In contrast, early glycation measured by furosine, but not AGEs, was associated with CAC score, implying hyperglycemia as a risk factor in calcium deposition perhaps via processes independent of glycation. Trial registration: Registered at Clinical trial reg. nos. NCT00360815 and NCT00360893, http://www.clinicaltrials.gov
format Online
Article
Text
id pubmed-4560872
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-45608722015-09-06 Skin collagen advanced glycation endproducts (AGEs) and the long-term progression of sub-clinical cardiovascular disease in type 1 diabetes Monnier, Vincent M Sun, Wanjie Gao, Xiaoyu Sell, David R Cleary, Patricia A Lachin, John M Genuth, Saul Cardiovasc Diabetol Original Investigation BACKGROUND: We recently reported strong associations between eight skin collagen AGEs and two solubility markers from skin biopsies obtained at DCCT study closeout and the long-term progression of microvascular disease in EDIC, despite adjustment for mean glycemia. Herein we investigated the hypothesis that some of these AGEs (fluorescence to be reported elsewhere) correlate with long-term subclinical cardiovascular disease (CVD) measurements, i.e. coronary artery calcium score (CAC) at EDIC year 7–9 (n = 187), change of carotid intima-media thickness (IMT) from EDIC year 1 to year 6 and 12 (n = 127), and cardiac MRI outcomes at EDIC year 15–16 (n = 142). METHODS: Skin collagen AGE measurements obtained from stored specimens were related to clinical data from the DCCT/EDIC using Spearman correlations and multivariable logistic regression analyses. RESULTS: Spearman correlations showed furosine (early glycation) was associated with future mean CAC (p < 0.05) and CAC >0 (p = 0.39), but not with CAC score <100 vs. >100. Glucosepane and pentosidine crosslinks, methylglyoxal hydroimidazolones (MG-H1) and pepsin solubility (inversely) correlated with IMT change from year 1 to 6(all P < 0.05). Left ventricular (LV) mass (cMRI) correlated with MG-H1, and inversely with pepsin solubility (both p < 0.05), while the ratio LV mass/end diastolic volume correlated with furosine and MG-H1 (both p < 0.05), and highly with CML (p < 0.01). In multivariate analysis only furosine (p = 0.01) was associated with CAC. In contrast IMT was inversely associated with lower collagen pepsin solubility and positively with glucosepane, CONCLUSIONS: In type 1 diabetes, multiple AGEs are associated with IMT progression in spite of adjustment for A1c implying a likely participatory role of glycation and AGE mediated crosslinking on matrix accumulation in coronary arteries. This may also apply to functional cardiac MRI outcomes, especially left ventricular mass. In contrast, early glycation measured by furosine, but not AGEs, was associated with CAC score, implying hyperglycemia as a risk factor in calcium deposition perhaps via processes independent of glycation. Trial registration: Registered at Clinical trial reg. nos. NCT00360815 and NCT00360893, http://www.clinicaltrials.gov BioMed Central 2015-09-05 /pmc/articles/PMC4560872/ /pubmed/26341632 http://dx.doi.org/10.1186/s12933-015-0266-4 Text en © Monnier et al. 2015 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Original Investigation
Monnier, Vincent M
Sun, Wanjie
Gao, Xiaoyu
Sell, David R
Cleary, Patricia A
Lachin, John M
Genuth, Saul
Skin collagen advanced glycation endproducts (AGEs) and the long-term progression of sub-clinical cardiovascular disease in type 1 diabetes
title Skin collagen advanced glycation endproducts (AGEs) and the long-term progression of sub-clinical cardiovascular disease in type 1 diabetes
title_full Skin collagen advanced glycation endproducts (AGEs) and the long-term progression of sub-clinical cardiovascular disease in type 1 diabetes
title_fullStr Skin collagen advanced glycation endproducts (AGEs) and the long-term progression of sub-clinical cardiovascular disease in type 1 diabetes
title_full_unstemmed Skin collagen advanced glycation endproducts (AGEs) and the long-term progression of sub-clinical cardiovascular disease in type 1 diabetes
title_short Skin collagen advanced glycation endproducts (AGEs) and the long-term progression of sub-clinical cardiovascular disease in type 1 diabetes
title_sort skin collagen advanced glycation endproducts (ages) and the long-term progression of sub-clinical cardiovascular disease in type 1 diabetes
topic Original Investigation
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4560872/
https://www.ncbi.nlm.nih.gov/pubmed/26341632
http://dx.doi.org/10.1186/s12933-015-0266-4
work_keys_str_mv AT monniervincentm skincollagenadvancedglycationendproductsagesandthelongtermprogressionofsubclinicalcardiovasculardiseaseintype1diabetes
AT sunwanjie skincollagenadvancedglycationendproductsagesandthelongtermprogressionofsubclinicalcardiovasculardiseaseintype1diabetes
AT gaoxiaoyu skincollagenadvancedglycationendproductsagesandthelongtermprogressionofsubclinicalcardiovasculardiseaseintype1diabetes
AT selldavidr skincollagenadvancedglycationendproductsagesandthelongtermprogressionofsubclinicalcardiovasculardiseaseintype1diabetes
AT clearypatriciaa skincollagenadvancedglycationendproductsagesandthelongtermprogressionofsubclinicalcardiovasculardiseaseintype1diabetes
AT lachinjohnm skincollagenadvancedglycationendproductsagesandthelongtermprogressionofsubclinicalcardiovasculardiseaseintype1diabetes
AT genuthsaul skincollagenadvancedglycationendproductsagesandthelongtermprogressionofsubclinicalcardiovasculardiseaseintype1diabetes
AT skincollagenadvancedglycationendproductsagesandthelongtermprogressionofsubclinicalcardiovasculardiseaseintype1diabetes